KIT and neoplasm: Because alternative mechanisms may drive tumor growth, alongside or independent of c-kit mutations, a more in-depth investigation into these mechanisms is recommended to support the use of TKIs alongside agents targeting putative activating mechanisms (e.g., inhibition of the downstream pathway).